18F-FDOPA PET and PET/CT Accurately Localize Pheochromocytomas
Open Access
- 16 March 2009
- journal article
- Published by Society of Nuclear Medicine in Journal of Nuclear Medicine
- Vol. 50 (4) , 513-519
- https://doi.org/10.2967/jnumed.108.058396
Abstract
Successful treatment of pheochromocytoma requires accurate diagnosis and localization of tumors. Herein, we investigated the accuracy of PET using 3,4-dihydroxy-6-18F-fluoro-phenylalanine (18F-FDOPA), an amino acid transporter substrate, as an independent marker for detection of benign and malignant pheochromocytomas. Methods: The study comprised 25 consecutive patients (9 men, 16 women) whose median age was 51 y (range, 25–68 y), with known or suspected pheochromocytoma. Eleven patients underwent standardized 18F-FDOPA PET and 14 patients underwent 18F-FDOPA PET/CT studies, with a median of 511 MBq of 18F-FDOPA (range, 206–625 MBq). Two readers, unaware of the reports of other imaging studies and clinical data, analyzed all scans visually and quantitatively (maximum standardized uptake value [SUVmax] and maximum transverse diameter). Histology and long-term clinical follow-up served as the gold standard. Correlation between SUVmax of tumors and biochemical markers was evaluated. SUVmax of the benign and malignant tumors was compared. Results: Seventeen patients underwent surgery. Histology confirmed pheochromocytoma or paraganglioma in 11 cases (8 adrenal, including 2 malignant tumors, and 3 extraadrenal, including 1 malignant tumor). The diagnosis of pheochromocytoma was established by follow-up in 2 additional patients (1 adrenal and 1 unknown location) and ruled out in 6 patients. Visual analysis detected and localized pheochromocytoma in 11 of 13 patients without false-positive results (sensitivity, 84.6%; specificity, 100%; accuracy, 92%). These lesions had an SUVmax of 2.3–34.9 (median, 8.3). Evaluation of the false-negative cases revealed a 13 × 5 mm lesion with an SUVmax of 1.96 in 1 case; no lesion was localized in the second case using multiple additional modalities. Spearman nonparametric analysis did not show statistically significant correlation between SUVmax of the tumors and biochemical markers. The Mann–Whitney nonparametric test did not demonstrate a statistically significant difference between the SUVmax of 18F-FDOPA in malignant and benign tumors. Conclusion: 18F-FDOPA PET and PET/CT are highly sensitive and specific tools that can provide additional independent information for diagnosis and localization of benign and malignant pheochromocytomas.Keywords
This publication has 24 references indexed in Scilit:
- Comparison of 6-18F-Fluorodopamine PET with 123I-Metaiodobenzylguanidine and 111In-Pentetreotide Scintigraphy in Localization of Nonmetastatic and Metastatic PheochromocytomaJournal of Nuclear Medicine, 2008
- Usefulness of Standardized Uptake Values for Distinguishing Adrenal Glands with Pheochromocytoma from Normal Adrenal Glands by Use of 6-18F-Fluorodopamine PETJournal of Nuclear Medicine, 2007
- The Effects of Carbidopa on Uptake of 6-18F-Fluoro-L-DOPA in PET of Pheochromocytoma and Extraadrenal Abdominal ParagangliomaJournal of Nuclear Medicine, 2007
- The role of 6-[18F]fluorodopamine positron emission tomography in the localization of adrenal pheochromocytoma associated with von Hippel–Lindau syndromeActa Endocrinologica, 2007
- Anatomical and Functional Imaging of Tumors in Animal ModelsAnnals of the New York Academy of Sciences, 2006
- [11C]Metahydroxyephedrine and [18F]Fluorodeoxyglucose Positron Emission Tomography Improve Clinical Decision Making in Suspected PheochromocytomaAnnals of Surgical Oncology, 2006
- Imaging of pheochromocytoma and paragangliomaFamilial Cancer, 2005
- Current Approaches and Recommended Algorithm for the Diagnostic Localization of PheochromocytomaJournal of Clinical Endocrinology & Metabolism, 2004
- Pheochromocytomas: Detection with11C Hydroxyephedrine PETRadiology, 2004
- Pheochromocytomas: Detection with18F DOPA Whole-Body PET—Initial ResultsRadiology, 2002